280 related articles for article (PubMed ID: 25748087)
1. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.
Kuiatse I; Baladandayuthapani V; Lin HY; Thomas SK; Bjorklund CC; Weber DM; Wang M; Shah JJ; Zhang XD; Jones RJ; Ansell SM; Yang G; Treon SP; Orlowski RZ
Clin Cancer Res; 2015 Jun; 21(11):2538-45. PubMed ID: 25748087
[TBL] [Abstract][Full Text] [Related]
2. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
3. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
4. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I; Eisele S; Remer I; Schmitz J; Zeschky K; Colberg C; Stachon P; Wolf D; Willecke F; Buchner M; Zirlik K; Ortiz-Rodriguez A; Lozhkin A; Hoppe N; von zur Muhlen C; zur Hausen A; Bode C; Zirlik A
Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1991-9. PubMed ID: 21700926
[TBL] [Abstract][Full Text] [Related]
5. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
Baluom M; Grossbard EB; Mant T; Lau DT
Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
[TBL] [Abstract][Full Text] [Related]
7. The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Can G; Ayvaz S; Can H; Demirtas S; Aksit H; Yilmaz B; Korkmaz U; Kurt M; Karaca T
J Crohns Colitis; 2015 Oct; 9(10):907-17. PubMed ID: 26116555
[TBL] [Abstract][Full Text] [Related]
8. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.
Ni H; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Hitoshi Y; Ansell SM; Treon SP; Thomas SK; Lee HC; Wang Z; Davis RE; Orlowski RZ
Clin Cancer Res; 2018 Dec; 24(24):6408-6420. PubMed ID: 30126942
[TBL] [Abstract][Full Text] [Related]
9. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
11. The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
Platt AM; Benson RA; McQueenie R; Butcher JP; Braddock M; Brewer JM; McInnes IB; Garside P
Rheumatology (Oxford); 2015 Jan; 54(1):169-77. PubMed ID: 25065010
[TBL] [Abstract][Full Text] [Related]
12. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
14. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
19. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
20. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
